Farmas USA

Confiemos que algún dia la veamos a 7....por ilusion que no falte!!

Anda y yo........ja jajajaja, la esperanza es lo último q se pierde.

Suerte con tus Nvax, q si ACHN me devuelve lo mío os seguiré desde dentro.

ya sabemos que esto de las farmas es una loteria, pero de momento está calentando motores ya que a final de mes tiene FDA, y entre esto y el contagio de IDIX, la hepatitis C tiene tirón.
tiene tambien un buen pipeline, y maximos en 12$... a ver si los vemos!!

hace una hora:
http://www.streetinsider.com/FDA/Achillion+Pharma+(ACHN)+Announces+Sovaprevir+Clinical+Hold+Removed/9567962.html

alguno se acuerda del lateral 6-7$ de primavera verano 2012 de ACHN ? que tiempos aquellos! :))))

por cierto, ayer me dio por mirar el konkorde de ACHN y me sorprendio el super nivelazo de entrada de sangre azul.
Pense, "y todo esto por empatia con IDIX" ? ..

pues igual va a ser que no era por eso!

CLSN

Compra EGEN a 14 kilos. Halted. Edito: +20,52% ahora mismo. Anda que no me falta a mí...

Celsion (CLSN) to Acquire EGEN in $14M Deal
Celsion (NASDAQ: CLSN) and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas" for delivery of DNA and mRNA, TheraSilence" for delivery of RNA, and RAST" for Cell Enabled Expression and Secretion of RNA.
Under the terms of the agreement, a wholly-owned subsidiary of Celsion will acquire the assets of EGEN and assume certain liabilities in exchange for cash and shares of Celsion totaling $14 million. The upfront payment consists of $10.6 million in Celsion common stock representing approximately 16.4% of Celsion's outstanding shares, of which $2.1 million in Celsion common stock is subject to a twenty-four month holdback by Celsion for expense adjustment and certain indemnification claims of Celsion, and $3.4 million in cash.
In addition to the upfront payment, a total of $30.4 million in future milestone obligations are payable to EGEN based on the successful completion of certain clinical development and licensing milestones. The acquisition is expected to close in June 2014, subject to customary closing conditions. The boards of directors of both Celsion and EGEN have unanimously approved the transaction. The transaction is not subject to Celsion shareholder approval.
The combination of Celsion and EGEN will create a fully-integrated, oncology-focused research and development company with a multi-phase clinical pipeline, platform technologies for the discovery of novel, nucleic acid-based immunotherapies and other anti-cancer DNA/RNA therapies, and expertise from bench to bedside. The transaction brings to Celsion EGEN's lead, Phase Ib clinical candidate, EGEN-001, an IL-12 plasmid immunotherapy encased in a nanoparticle delivery system, as well as three technology platforms, TheraPlas", TheraSilence", and RAST" for Cell Enabled Expression and Secretion of RNA.
The transaction complements Celsion's lead development candidate, ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently advancing in a pivotal, double-blind, placebo-controlled, global Phase III trial (the OPTIMA Study) in primary liver cancer.

PD: Al final tenía razón el de SA (ahora no recuerdo el nombre). A ver qué nos da ahora...

que recuerdos achn y decían que era un muerto

actc

otra vez a 0.05 oportunidad de entrada.